MCID: MCP006
MIFTS: 47

Mucoepidermoid Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases

Aliases & Classifications for Mucoepidermoid Carcinoma

About this section

Aliases & Descriptions for Mucoepidermoid Carcinoma:

Name: Mucoepidermoid Carcinoma 10 45 12 65
Carcinoma, Mucoepidermoid 36
 
Carcinoma Mucoepidermoid 47
Mec 10

Classifications:



External Ids:

Disease Ontology10 DOID:4531
MeSH36 D018277
SNOMED-CT59 4079000
NCIt42 C3772
UMLS65 C0206694

Summaries for Mucoepidermoid Carcinoma

About this section
NIH Rare Diseases:45 Mucoepidermoid carcinoma is a type of cancer of the salivary glands.  salivary gland cancer is diagnosed in 2-3 individuals per 100,000 people each year, and 30-35% of these are mucoepidermoid carcinomas.   mucoepidermoid carcinoma develops when a cell randomly acquires changes (mutations) in genes that regulate how the cell divides such that it begins to grow quickly, forming a cluster of cells (a mass or lump).  the earliest signs of a mucoepidermoid carcinoma may include a lump in the face, neck, or mouth; numbness, weakness, or pain in part of the face; or difficulty swallowing.  treatment often begins with surgery to remove the entire tumor.  in some cases, radiation therapy and/or chemotherapy may be used after surgery to ensure that no cancer cells remain in the body. last updated: 6/18/2013

MalaCards based summary: Mucoepidermoid Carcinoma, also known as carcinoma, mucoepidermoid, is related to lacrimal gland mucoepidermoid carcinoma and bile duct mucoepidermoid carcinoma. An important gene associated with Mucoepidermoid Carcinoma is CRTC1 (CREB Regulated Transcription Coactivator 1), and among its related pathways are Central carbon metabolism in cancer and Glucocorticoid receptor regulatory network. Affiliated tissues include salivary gland, brain and thyroid, and related mouse phenotypes are limbs/digits/tail and tumorigenesis.

Disease Ontology:10 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells.

Wikipedia:68 Mucoepidermoid carcinoma is the most common type of salivary gland malignancy in adults. Mucoepidermoid... more...

Related Diseases for Mucoepidermoid Carcinoma

About this section

Diseases related to Mucoepidermoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 549)
idRelated DiseaseScoreTop Affiliating Genes
1lacrimal gland mucoepidermoid carcinoma34.5CRTC1, MAML2
2bile duct mucoepidermoid carcinoma33.7ERBB2, KRT14, KRT5
3mucoepidermoid esophageal carcinoma33.1CRTC1, MAML2
4cutaneous mucoepidermoid carcinoma33.0KRT5, MUC1, MUC2, MUC4, MUC5AC
5lupus erythematosus30.9EGFR, ERBB2, MAML2
6papillary carcinoma30.1CDH1, ERBB2, MUC1, MUC2
7pancreatic cancer30.0CDH1, EGFR, TP53
8scabies29.9TG, TP53
9gastrointestinal stromal tumor29.8CDH1, EGFR, ERBB2, TP53
10liver cirrhosis29.8KRT13, MUC4, MUC5AC, TP63
11breast cancer28.1CDH1, CDH3, EGFR, ERBB2, KRT14, KRT5
12sclerosing mucoepidermoid carcinoma with eosinophilia12.5
13thymus mucoepidermoid carcinoma12.5
14breast mucoepidermoid carcinoma12.5
15lung mucoepidermoid carcinoma12.4
16laryngeal mucoepidermoid carcinoma12.4
17bronchus mucoepidermoid carcinoma12.3
18trachea mucoepidermoid carcinoma12.3
19paranasal sinus cancer11.6
20mucoepidermoid thyroid carcinoma11.4
21spiradenoma10.5CRTC1, MAML2
22flat ductal epithelial atypia10.5EGFR, ERBB2
23ceruminous carcinoma10.5
24adenofibroma10.5EGFR, ERBB2
25her2-receptor positive breast cancer10.5EGFR, ERBB2
26adenosquamous pancreas carcinoma10.5CRTC1, EGFR, MAML2
27vulvitis10.5CRTC1, MAML2, MUC1
28eccrine papillary adenocarcinoma10.4EGFR, ERBB2
29pagod syndrome10.4ERBB2, MUC1
30situs inversus10.4EGFR, ERBB2, MUC1
31recurrent hypersomnia10.4CRTC1, EGFR, MAML2
32leukemia10.4
33protein-deficiency anemia10.4EGFR, ERBB2
34kidney osteogenic sarcoma10.4HMGA2, MUC4
35lymphoma10.4
36endotheliitis10.4
37epidermal nevus vitamin d resistant rickets10.4EGFR, ERBB2, MUC1
38gastroschisis10.4
39venous hemangioma10.4MUC1, MUC4
40neuronitis10.4
41lymphatic system disease10.4EGFR, TP53
42hypogonadotropic hypogonadism-frontoparietal alopecia syndrome10.3EGFR, TP53
43hepatitis10.3
44glycogen-rich clear cell breast carcinoma10.3KRT14, MAML2
45appendix lymphoma10.3CDH1, MUC1, MUC2
46gastric cardia carcinoma10.3CDH1, EGFR, ERBB2
47bile duct signet ring cell carcinoma10.3CDH1, MUC1, MUC2
48myocardial infarction10.3
49prostatitis10.3
50cerebritis10.3

Graphical network of the top 20 diseases related to Mucoepidermoid Carcinoma:



Diseases related to mucoepidermoid carcinoma

Symptoms for Mucoepidermoid Carcinoma

About this section

Drugs & Therapeutics for Mucoepidermoid Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Emend15 41 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
FDA Label: Emend
Disease/s that Drug Treats:Chemotherapy-induced Nausea and Vomiting
Indications and Usage:15 EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist,indicated: in combination with other antiemetic agents for the:o prevention of acute and delayed nausea and vomitingassociated with initial and repeat courses of highly emetogeniccancer chemotherapy (HEC) including high-dose cisplatin (1.1)o prevention of nausea and vomiting associated with initial andrepeat courses of moderately emetogenic cancer chemotherapy(MEC) (1.1) for the prevention of postoperative nausea and vomiting (PONV)(1.2)Limitations of Use (1.3) Not studied for the treatment of established nausea and vomiting. Chronic continuous administration is not recommended.
DrugBank Targets:13 1. Substance-P receptor
Mechanism of Action:15 
Target: emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin
Action: inhibitor
FDA: Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targetsof existing therapies for chemotherapy-induced nausea and vomiting (CINV) and postoperative nauseaand vomiting (PONV).Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxicchemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron EmissionTomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupiesbrain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity ofthe 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both theacute and delayed phases of cisplatin-induced emesis.

Drugs for Mucoepidermoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 144)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
2
FluconazoleapprovedPhase 2, Phase 317186386-73-43365
Synonyms:
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
86386-73-4
AC-428
AC1L1FRQ
AC1Q77FV
AKOS000280854
AbZ Brand of Fluconazole
Afungil
Alflucoz
Aliud Brand of Fluconazole
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
BIDD:GT0799
BRD-K05977355-001-02-6
BSPBio_003504
Baten
Beagyne
Bio-0041
Biocanol
Biozole
Biozolene
C13H12F2N6O
CCRIS 7211
CHEBI:46081
CHEMBL106
CID3365
CPD000471882
Canesoral
Canzol
Chemia Brand of Fluconazole
Cryptal
D00322
D015725
DB00196
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
DRG-0005
Diflazon
Diflucan
Diflucan (TN)
Diflucan, Trican, Alfumet, Fluconazole
Dimycon
DivK1c_001030
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc Hexal
Flucazol
FlucoLich
Flucobeta
Fluconazol
Fluconazol AL
Fluconazol AbZ
Fluconazol Isis
Fluconazol Stada
Fluconazol [Spanish]
Fluconazol ratiopharm
Fluconazol von ct
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazole
Fluconazole & Bovine Lactoferrin
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole & hGCSF
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazolum
Fluconazolum [Latin]
Flucostat
 
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
Hexal Brand of Fluconazole
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
LS-1858
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mack Brand of Fluconazole
MolPort-000-883-859
MolPort-002-885-825
Monicure
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
NINDS_001030
Neofomiral
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
S1331_Selleck
SAM002589905
SAT Brand of Fluconazole
SMR000471882
SPBio_001613
SPECTRUM1503975
STK619301
Silanes Brand of Fluconazole
Solacap
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
UNII-8VZV102JFY
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
ZINC00004009
Zemyc
Zoltec
Zonal
betapharm Brand of Fluconazole
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
fluconazole
nchembio.100-comp3
nchembio.65-comp15
ratiopharm Brand of Fluconazole
3
Miconazoleapproved, investigationalPhase 2, Phase 3, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
CevimelineapprovedPhase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline Hydrochloride
 
Cevimeline [INN]
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
5
Megestrol acetateapprovedPhase 360595-33-511683
Synonyms:
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17α-Acetoxy-6-dehydro-6-methylprogesterone
17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17α-acetoxyprogesterone
6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17α-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate
 
6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone
MGA
Magestin
Maygace
Megace
Megace Es
Megeron
Megestat
Megestil
Megestin
Megestol
Megestrol
Megestrol Acetate
Niagestin
Ovaban
Ovarid
Volidan
6
DoxepinapprovedPhase 3131668-19-5667477, 667468
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
3607-18-9
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
AKOS001582771
Adapin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
Curatin
D07875
DB01142
DivK1c_000431
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin Hcl
Doxepin Hydrochloride
Doxepin Hydrochloride,
Doxepin [USAN]
 
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepinum
Doxepinum [INN-Latin]
HSDB 3069
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
LS-174582
LS-61638
Lopac-D-4526
Lopac0_000339
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Prudoxin
Quitaxon
SPBio_000206
SPBio_002325
Silenor
Sinequan
Sinequan (TN)
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Spectrum_000805
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Zonalon
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
cis-doxepin
doxepin
7
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
8
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 2, Phase 11844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
9Antineoplastic Agents, HormonalPhase 34256
10Hormone AntagonistsPhase 2, Phase 310002
11Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 2, Phase 39988
12HormonesPhase 2, Phase 3, Phase 111748
13Contraceptive AgentsPhase 31706
14Antimitotic AgentsPhase 3, Phase 2, Phase 14296
15AnalgesicsPhase 39358
16
MegestrolPhase 3603562-63-819090, 3080587
Synonyms:
(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
3562-63-8
AC1L2DG3
C07120
CID19090
Chronopil
Chronopil (TN)
D008535
D08167
DB00351
 
EINECS 222-628-6
HSDB 3233
LS-118488
MGA
Megestrol (INN)
Megestrol Acetate
Megestrol [INN:BAN]
Megestrolo
Megestrolo [DCIT]
Megestrolum [INN-Latin]
Megestryl acetate
UNII-EA6LD1M70M
megestrol
17Contraceptives, OralPhase 33734
18Central Nervous System StimulantsPhase 31721
19Appetite StimulantsPhase 358
20Cytochrome P-450 CYP2C9 InhibitorsPhase 2, Phase 3497
21Central Nervous System DepressantsPhase 310016
22Tubulin ModulatorsPhase 3, Phase 2, Phase 14279
23Anesthetics, IntravenousPhase 31943
24Anesthetics, GeneralPhase 32274
25Analgesics, OpioidPhase 32304
26AnestheticsPhase 37385
27Liver ExtractsPhase 3, Phase 2, Phase 13572
28NarcoticsPhase 32709
29Antifungal AgentsPhase 2, Phase 3, Phase 13015
30Anti-Infective AgentsPhase 2, Phase 3, Phase 117220
31Neurotransmitter AgentsPhase 314795
32Cholinergic AgentsPhase 33243
33pancreatic polypeptidePhase 3, Phase 120
34Peripheral Nervous System AgentsPhase 318510
35Cytochrome P-450 Enzyme InhibitorsPhase 2, Phase 33036
36Psychotropic DrugsPhase 35501
37Histamine AntagonistsPhase 3826
38Antidepressive AgentsPhase 32367
39Antidepressive Agents, TricyclicPhase 3250
40
histaminePhase 390675614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
41ColaNutraceuticalPhase 3, Phase 1, Phase 21768
42
Oxaliplatinapproved, investigationalPhase 2132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
43
HydroxyureaapprovedPhase 1, Phase 2188127-07-13657
Synonyms:
1-HYDROXYUREA
127-07-1
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
BRN 1741548
BSPBio_002164
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
C07044
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
Carbamohydroxamic Acid
Carbamohydroxamic acid
Carbamohydroximic Acid
Carbamohydroximic acid
Carbamohydroxyamic Acid
Carbamohydroxyamic acid
Carbamoyl Oxime
Carbamoyl oxime
Carbamyl Hydroxamate
Carbamyl hydroxamate
Carrbamoyl Oxime
D00341
D006918
DB01005
DRG-0253
DivK1c_000556
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
HYDREA (TN)
HYDROXY-UREA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
Hydrea
Hydrea (TM)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
Hydroxyurea
Hydroxyurea (D4)
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
 
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [DCIT]
Idrossicarbamide [Dcit]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
LS-709
Litaler
Litalir
Lopac-H-8627
Lopac0_000596
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
NCI C04831
NCI-C04831
NCI60_002773
NCIMech_000139
NHY
NINDS_000556
NSC 32065
NSC32065
Onco-Carbide
Onco-carbide
Oncocarbide
Oxyurea
S-phase/G-1 interface inhibitor
S1896_Selleck
SK 22591
SMR000059149
SPBio_000247
SPECTRUM1500344
SQ 1089
SQ-1089
Siklos
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
Spectrum_000909
Sterile Urea
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
carbamide oxide
hydroxyaminomethanamide
hydroxyurea
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
tetratogen: inhibits ribonucleoside diphosphate reductase
44
AldesleukinapprovedPhase 238785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
45
Doxorubicinapproved, investigationalPhase 2158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
46
CetuximabapprovedPhase 1, Phase 2713205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
 
Cetuximab (genetical recombination) (JAN)
D03455
Erbitux
Erbitux (TN)
IMC-C225
cetuximab
47
GemcitabineapprovedPhase 2, Phase 1188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
48
Bevacizumabapproved, investigationalPhase 2, Phase 11875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
49
EpirubicinapprovedPhase 1, Phase 236156420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
50
Trastuzumabapproved, investigationalPhase 2, Phase 1726180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab

Interventional clinical trials:

(show top 50)    (show all 79)
idNameStatusNCT IDPhase
1Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
2Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
3Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
4Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
5Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
6Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
7Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
8Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00041171Phase 3
9Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2
10Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1, Phase 2
11Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2
12Docetaxel in Treating Patients With Solid TumorsCompletedNCT00003565Phase 2
13Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1, Phase 2
14Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck CancerCompletedNCT00448552Phase 2
15Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
16Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1, Phase 2
17Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth CancerCompletedNCT00004901Phase 1, Phase 2
18Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland TumorCompletedNCT00079079Phase 2
19Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung CancerCompletedNCT00021333Phase 2
20Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck CancerCompletedNCT00509665Phase 2
21Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland CancerCompletedNCT00002632Phase 2
22Intensity-Modulated or Proton Radiation Therapy for Sinonasal MalignancyRecruitingNCT01586767Phase 2
2318F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyRecruitingNCT01806675Phase 1, Phase 2
24External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesRecruitingNCT00637637Phase 2
25Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By SurgeryRecruitingNCT01220583Phase 2
26Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsActive, not recruitingNCT00859937Phase 2
27Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck CancerActive, not recruitingNCT00003251Phase 1, Phase 2
28Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable CancerActive, not recruitingNCT00003657Phase 2
29Antineoplaston Therapy in Treating Patients With Advanced Head and Neck CancerActive, not recruitingNCT00003489Phase 2
30Trastuzumab in Treating Patients With Advanced Salivary Gland CancerActive, not recruitingNCT00004163Phase 2
31Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During SurgeryActive, not recruitingNCT00003744Phase 2
32Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By SurgeryActive, not recruitingNCT00101075Phase 2
33Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland CancerTerminatedNCT00126607Phase 2
34Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
35Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
36Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
377-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
38Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
39Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
40Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerCompletedNCT01637194Phase 1
41Head & Neck Cancer Survivorship: Physical and Functional StatusCompletedNCT00751816Phase 1
42Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
43Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced CancerCompletedNCT00045006Phase 1
44Vaccine Therapy in Treating Patients With Advanced or Recurrent CancerCompletedNCT00019110Phase 1
45Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00010023Phase 1
46Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT00006036Phase 1
47Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver FunctionCompletedNCT00002901Phase 1
48Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
49Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid TumorsCompletedNCT01172028Phase 1
50Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid TumorsCompletedNCT00014456Phase 1

Search NIH Clinical Center for Mucoepidermoid Carcinoma


Cochrane evidence based reviews: carcinoma, mucoepidermoid

Genetic Tests for Mucoepidermoid Carcinoma

About this section

Anatomical Context for Mucoepidermoid Carcinoma

About this section

MalaCards organs/tissues related to Mucoepidermoid Carcinoma:

33
Salivary gland, Brain, Thyroid, Lung, Liver, Breast, Kidney

Animal Models for Mucoepidermoid Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Mucoepidermoid Carcinoma:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053718.6EGFR, ERBB2, KRT5, THBS1, TP53, TP63
2MP:00020067.9CDH1, EGFR, ERBB2, KRT14, MUC2, THBS1
3MP:00053897.8CDH1, CRTC1, EGFR, ERBB2, KRT14, THBS1
4MP:00107717.3CDH1, CDH3, EGFR, ERBB2, KRT14, KRT5
5MP:00053816.7CDH1, EGFR, ERBB2, KRT14, KRT5, MUC2
6MP:00053796.4CDH1, CDH3, CRTC1, EGFR, ERBB2, KRT14
7MP:00053786.2CDH1, CRTC1, EGFR, ERBB2, KRT14, KRT5
8MP:00053765.7CDH1, CRTC1, EGFR, ERBB2, KRT14, MUC2

Publications for Mucoepidermoid Carcinoma

About this section

Articles related to Mucoepidermoid Carcinoma:

(show top 50)    (show all 603)
idTitleAuthorsYear
1
Predictors of the Treatment Response of Spontaneous Intracranial Hypotension to an Epidural Blood Patch. (27149484)
2016
2
HMGCR positively regulated the growth and migration of glioblastoma cells. (26432005)
2016
3
Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration. (26073123)
2015
4
Chemically induced acute model of sarcosinemia in wistar rats. (26563127)
2015
5
Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. (23953881)
2014
6
A functional role for NS5ATP9 in the induction of HCV NS5A-mediated autophagy. (24750205)
2014
7
Recurrent lipoblastoma of upper extremity in a 9-year-old boy. (24713710)
2014
8
Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency. (23371835)
2013
9
Ezrin interacts with the SARS coronavirus Spike protein and restrains infection at the entry stage. (23185364)
2012
10
Changes in cholinergic amacrine cells after rodent anterior ischemic optic neuropathy (rAION). (20847114)
2011
11
Stimulation of adenosine A(2B) receptors induces interleukin-6 secretion in cardiac fibroblasts via the PKC-delta-P38 signalling pathway. (20050850)
2010
12
The molecular chaperone Hsp90 regulates accumulation of DNA polymerase eta at replication stalling sites in UV-irradiated cells. (20129057)
2010
13
Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. (19722212)
2009
14
The rs1990760 polymorphism within the IFIH1 locus is not associated with Graves' disease, Hashimoto's thyroiditis and Addison's disease. (19961590)
2009
15
Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. (19427181)
2009
16
Tumor necrosis factor-alpha decreases aquaporin-3 expression in DJM-1 keratinocytes. (19619514)
2009
17
Colon perforation during antiangiogenic therapy for malignant glioma. (18757774)
2009
18
Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. (19703551)
2009
19
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. (19508976)
2009
20
Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma. (19331667)
2009
21
Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. (18464119)
2008
22
Efalizumab-induced hypertrichosis. (18363750)
2008
23
Myocardial infarction and angina pectoris in the history of Polish medicine. Part 2. Diagnosis and early attempts at treatment: the 19th and 20th centuries. (18575427)
2008
24
Tuberous sclerosis complex: a tale of two genes. (18347312)
2008
25
Large deletions of the PRKAR1A gene in Carney complex. (18223213)
2008
26
Homogeneous TR-FRET high-throughput screening assay for calcium-dependent multimerization of sorcin. (17579123)
2007
27
Therapeutic potential of an adenovirus expressing p73 beta, a p53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo. (16481734)
2006
28
Childhood chorea-encephalopathy associated with human parvovirus B19 infection. (16700948)
2006
29
Tgf-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. (16178483)
2005
30
Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. (14964537)
2004
31
Overexpression of GSK3betaS9A resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3beta transgenic mice. (15517997)
2004
32
Acrocallosal syndrome: report of five Turkish patients. (15365461)
2004
33
Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. (12802802)
2003
34
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. (12707429)
2003
35
Sodium selenite, dietary micronutrient, prevents the lymphocyte DNA damage induced by N-nitrosodiethylamine and phenobarbital promoted experimental hepatocarcinogenesis. (12532333)
2003
36
Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. (12753256)
2003
37
A third isoform of cytochrome c oxidase subunit VIII is present in mammals. (12909344)
2003
38
Comparative 17beta-estradiol response and lipoprotein interactions of an avian apolipoprotein. (12161206)
2002
39
Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. (11843038)
2002
40
Screening for an AIRE-1 mutation in patients with Addison's disease, type 1 diabetes, Graves' disease and Hashimoto's thyroiditis as well as in APECED syndrome. (11298085)
2001
41
Ligand-independent GLUT4 translocation induced by guanosine 5'-O-(3-thiotriphosphate) involves tyrosine phosphorylation. (9421434)
1998
42
Transcriptional regulation of the human erythroid 5-aminolevulinate synthase gene. Identification of promoter elements and role of regulatory proteins. (9334239)
1997
43
Defective myogenesis in NFB-s mutant associated with a saturable suppression of MYF5 activity. (9039845)
1996
44
Infrequent expression of the MAGE gene family in uveal melanomas. (8647642)
1996
45
Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum. (7882384)
1995
46
Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. (8386265)
1993
47
Subtypes of alpha 1- and alpha 2-adrenergic receptors. (1346768)
1992
48
Renal cell carcinoma of the native kidney in a female renal allograft patient without acquired cystic kidney disease. (1630555)
1992
49
Becker and limb-girdle muscular dystrophy associated with pituitary dwarfism. (3655848)
1987
50
Periosteal chondroma: another cause of carpal tunnel syndrome. (6721390)
1984

Variations for Mucoepidermoid Carcinoma

About this section

Cosmic variations for Mucoepidermoid Carcinoma:

7 (show top 50)    (show all 104)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM483HRASsalivary gland,mouth floor,carcinoma,NS3
2COSM484HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
3COSM483HRASsalivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma3
4COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
5COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
6COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
7COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
8COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
9COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
10COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
11COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
12COSM483HRASsalivary gland,mouth floor,carcinoma,NS3
13COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
14COSM491HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
15COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
16COSM484HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
17COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
18COSM491HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
19COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
20COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
21COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
22COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
23COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinoma3
24COSM483HRASsalivary gland,parotid,carcinoma,mucoepidermoid carcinoma1
25COSM483HRASsalivary gland,parapharyngeal,carcinoma,mucoepidermoid carcinoma1
26COSM483HRASsalivary gland,parotid,carcinoma,mucoepidermoid carcinoma1
27COSM483HRASsalivary gland,maxillary sinus,carcinoma,mucoepidermoid carcinoma1
28COSM491HRASsalivary gland,maxillary sinus,carcinoma,mucoepidermoid carcinoma1
29COSM484HRASsalivary gland,submandibular,carcinoma,mucoepidermoid carcinoma1
30COSM483HRASsalivary gland,maxillary sinus,carcinoma,mucoepidermoid carcinoma1
31COSM483HRASsalivary gland,parotid,carcinoma,mucoepidermoid carcinoma1
32COSM483HRASsalivary gland,parotid,carcinoma,mucoepidermoid carcinoma1
33COSM44853TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
34COSM44853TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
35COSM43680TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
36COSM46282TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
37COSM46283TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
38COSM46283TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
39COSM44850TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
40COSM46282TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
41COSM43680TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
42COSM44850TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
43COSM43797TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
44COSM43797TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
45COSM44119TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
46COSM44119TP53salivary gland,NS,carcinoma,mucoepidermoid carcinoma3
47COSM46282TP53salivary gland,parotid,carcinoma,mucoepidermoid carcinoma1
48COSM46283TP53salivary gland,parotid,carcinoma,mucoepidermoid carcinoma1
49COSM44853TP53salivary gland,parotid,carcinoma,mucoepidermoid carcinoma1
50COSM43680TP53salivary gland,major,carcinoma,mucoepidermoid carcinoma1

Expression for genes affiliated with Mucoepidermoid Carcinoma

About this section
Search GEO for disease gene expression data for Mucoepidermoid Carcinoma.

Pathways for genes affiliated with Mucoepidermoid Carcinoma

About this section

Pathways related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
idSuper pathwaysScoreTop Affiliating Genes
19.6EGFR, ERBB2, TP53
29.5KRT14, KRT5, TP53
39.3CDH1, EGFR, ERBB2
49.3CDH1, EGFR, ERBB2
5
Show member pathways
9.2MUC1, MUC2, MUC4, MUC5AC
6
Show member pathways
9.1CDH1, EGFR, ERBB2, MUC1
79.1EGFR, ERBB2, THBS1, TP53
89.1EGFR, ERBB2, THBS1, TP53
9
Show member pathways
9.0CDH1, EGFR, ERBB2, TP53
108.7CDH1, EGFR, ERBB2, MUC1, TP53
11
Show member pathways
8.7MUC1, MUC2, MUC4, MUC5AC, THBS1
12
Show member pathways
8.7MUC1, MUC2, MUC4, MUC5AC, THBS1
138.4CDH1, EGFR, ERBB2, THBS1, TP53
148.3EGFR, ERBB2, HMGA2, THBS1, TP53, TP63
15
Show member pathways
7.9EGFR, ERBB2, MAML2, MUC1, MUC2, MUC4

GO Terms for genes affiliated with Mucoepidermoid Carcinoma

About this section

Cellular components related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1keratin filamentGO:00450959.6KRT13, KRT14, KRT5

Biological processes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1maintenance of gastrointestinal epitheliumGO:003027710.6MUC2, MUC4
2entrainment of circadian clock by photoperiodGO:004315310.5CRTC1, TP53
3hemidesmosome assemblyGO:003158110.4KRT14, KRT5
4DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.9MUC1, TP53, TP63
5O-glycan processingGO:00162669.8MUC1, MUC4, MUC5AC
6epithelial cell differentiationGO:00308559.7KRT14, MUC1, TP63
7negative regulation of apoptotic processGO:00430668.7EGFR, HMGA2, THBS1, TP53, TP63
8positive regulation of transcription from RNA polymerase II promoterGO:00459448.5CRTC1, EGFR, HMGA2, MAML2, TP53, TP63

Molecular functions related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:00047169.9EGFR, ERBB2

Sources for Mucoepidermoid Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet